The long-term benefits of a single dose of their gene therapy AAV1/SERCA2a in advanced heart failure patients was reported by researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai on Nov. 19 at the American Heart Association Scientific Sessions 2013. The new long-term follow-up results from their initial Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID 1) clinical trial found ...You have just read an article categorized health
titled Advanced Heart Failure Patients Benefit From Long-lasting Gene Therapy.
Written by:
editor - Friday, November 29, 2013
There are currently no comments for "Advanced Heart Failure Patients Benefit From Long-lasting Gene Therapy"
Post a Comment